Author

C. U. Blank

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1

Frequent Co-Authors

A. Shahrabi· 1 shared B. de Bruijn· 1 shared D. J. Adams· 1 shared D. Rao· 1 shared D. S. Peeper· 1 shared D. W. Vredevoogd· 1 shared E. A. Rozeman· 1 shared E. Hoefsmit· 1 shared

Activity by Year

2020-2020 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Shahrabi

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Nafamostat Mesylate in lipid carrier for nasal SARS-CoV2 titer reduction in a hamster model

L. Cornelissen, E. Hoefsmit, D. Rao, J. Lijnsvelt, L. ven Keulen, M. van Es, V. Grimm, R. H. Medema, C. U. Blank

This study tests nasal application of nafamostat mesylate in liposomes to reduce SARS-CoV-2 viral load in hamsters, finding reduced nasal titer but no improvement in disease severity.

bioRxiv · Nov 9, 2020 · PreprintMicrobiology

PREDICTIVE IMMUNE CHECKPOINT BLOCKADE CLASSIFIERS DISTINGUISHING MONO- VERSUS COMBINATION THERAPY REQUIREMENT

O. Krijgsman, K. Kemper, J. Boshuizen, D. W. Vredevoogd, E. A. Rozeman, S. Ibanez Molero, B. de Bruijn, P. Cornelissen-Steijger, A. Shahrabi, M. Del Castillo Velasco-Herrera, J.-Y. Song, M. A. Ligtenberg, R. J. C. Kluin, T. Kuilman, P. Ross-MacDonald, , D. S. Peeper

This paper develops two genetic signatures, InTumor and ExTumor, to predict immune checkpoint blockade response in melanoma patients, enabling stratification for monotherapy or combination therapy.

bioRxiv · Jul 14, 2020 · PreprintCancer Biology